Viral SERPINS-A Family of Highly Potent Immune-Modulating Therapeutic Proteins.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
15 09 2023
Historique:
received: 28 06 2023
revised: 03 08 2023
accepted: 06 09 2023
medline: 4 10 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Serine protease inhibitors, SERPINS, are a highly conserved family of proteins that regulate serine proteases in the central coagulation and immune pathways, representing 2-10% of circulating proteins in the blood. Serine proteases form cascades of sequentially activated enzymes that direct thrombosis (clot formation) and thrombolysis (clot dissolution), complement activation in immune responses and also programmed cell death (apoptosis). Virus-derived serpins have co-evolved with mammalian proteases and serpins, developing into highly effective inhibitors of mammalian proteolytic pathways. Through interacting with extracellular and intracellular serine and cysteine proteases, viral serpins provide a new class of highly active virus-derived coagulation-, immune-, and apoptosis-modulating drug candidates. Viral serpins have unique characteristics: (1) function at micrograms per kilogram doses; (2) selectivity in targeting sites of protease activation; (3) minimal side effects at active concentrations; and (4) the demonstrated capacity to be modified, or fine-tuned, for altered protease targeting. To date, the virus-derived serpin class of biologics has proven effective in a wide range of animal models and in one clinical trial in patients with unstable coronary disease. Here, we outline the known viral serpins and review prior studies with viral serpins, considering their potential for application as new sources for immune-, coagulation-, and apoptosis-modulating therapeutics.

Identifiants

pubmed: 37759793
pii: biom13091393
doi: 10.3390/biom13091393
pmc: PMC10526531
pii:
doi:

Substances chimiques

Serpins 0
Serine Proteinase Inhibitors 0
Serine Endopeptidases EC 3.4.21.-
Serine Proteases EC 3.4.-

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR074627
Pays : United States

Références

Nat Rev Genet. 2002 Oct;3(10):759-68
pubmed: 12360234
J Leukoc Biol. 2009 Mar;85(3):418-26
pubmed: 19052145
Front Cardiovasc Med. 2021 Jun 04;8:649124
pubmed: 34164439
J Exp Med. 1998 Jun 1;187(11):1799-811
pubmed: 9607921
Biochem Biophys Res Commun. 2000 Jun 24;273(1):101-9
pubmed: 10873571
J Virol. 2003 Oct;77(20):11158-69
pubmed: 14512563
Sci Adv. 2020 Oct 21;6(43):
pubmed: 33087346
J Virol. 1998 Jan;72(1):452-9
pubmed: 9420245
J Gen Virol. 1998 Jan;79 ( Pt 1):149-53
pubmed: 9460936
J Clin Med. 2019 Oct 04;8(10):
pubmed: 31590323
Gene Ther. 2003 Sep;10(20):1781-90
pubmed: 12939645
PLoS One. 2010 May 06;5(5):e10510
pubmed: 20463901
PLoS One. 2014 Oct 29;9(10):e111353
pubmed: 25354050
Circulation. 2000 Apr 4;101(13):1598-605
pubmed: 10747355
Mol Biol Evol. 2018 Nov 1;35(11):2607-2617
pubmed: 30099520
PLoS One. 2015 Feb 06;10(2):e0115482
pubmed: 25658487
Expert Opin Investig Drugs. 2000 Sep;9(9):2051-68
pubmed: 11060792
Front Cardiovasc Med. 2021 Mar 31;8:648349
pubmed: 33869308
Virology. 2000 Jul 5;272(2):281-92
pubmed: 10873771
J Gen Virol. 2015 May;96(Pt 5):1150-1160
pubmed: 25573886
Circ Cardiovasc Interv. 2010 Dec;3(6):543-8
pubmed: 21062996
J Virol. 2004 Mar;78(6):2770-9
pubmed: 14990697
Circulation. 1996 Dec 1;94(11):2890-900
pubmed: 8941118
Front Allergy. 2022 Mar 31;3:835503
pubmed: 35958943
Neurobiol Dis. 2003 Oct;14(1):1-9
pubmed: 13678661
Thromb Haemost. 2021 Mar;121(3):261-269
pubmed: 32987444
J Virol. 1995 Dec;69(12):7688-98
pubmed: 7494278
J Thromb Haemost. 2007 Jul;5 Suppl 1:102-15
pubmed: 17635716
Clin Immunol. 2014 Aug;153(2):254-63
pubmed: 24845791
Virology. 2003 Feb 15;306(2):289-302
pubmed: 12642102
PLoS One. 2012;7(9):e44694
pubmed: 23049756
J Biol Chem. 2001 Sep 7;276(36):33293-6
pubmed: 11435447
Biochemistry. 2018 Feb 20;57(7):1096-1107
pubmed: 29227673
J Clin Med. 2020 Apr 11;9(4):
pubmed: 32290480
Nature. 1992 Jun 18;357(6379):605-7
pubmed: 1608473
J Biol Chem. 2003 May 16;278(20):18563-72
pubmed: 12637546
Shock. 1997 Nov;8(5):328-34
pubmed: 9361342
J Clin Oncol. 2014 Oct 1;32(28):3103-10
pubmed: 25113756
Transplantation. 2006 Mar 27;81(6):908-14
pubmed: 16570016
J Biol Chem. 2010 Jun 25;285(26):19997-20005
pubmed: 20427266
Mol Biol Evol. 2021 Jun 25;38(7):2915-2929
pubmed: 33744972
Clin Immunol. 2021 Aug;229:108764
pubmed: 34089860
EMBO Mol Med. 2023 Jun 7;15(6):e17144
pubmed: 37158379
Cytokine. 2014 Jan;65(1):79-87
pubmed: 24211016
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9108-13
pubmed: 8799162
Thromb Haemost. 2006 Mar;95(3):499-510
pubmed: 16525579
Lancet. 2002 Jun 29;359(9325):2242-7
pubmed: 12103288
J Biol Chem. 1993 Jan 5;268(1):516-21
pubmed: 8416956
Virology. 1993 Aug;195(2):348-63
pubmed: 8337817
Biomedicines. 2020 Sep 23;8(10):
pubmed: 32977430
Antimicrob Agents Chemother. 2013 Sep;57(9):4114-27
pubmed: 23774438
Circ Res. 2003 Sep 5;93(5):464-71
pubmed: 12919945
EMBO Rep. 2011 Sep 30;12(10):1011-7
pubmed: 21909074
Eur J Hum Genet. 2004 Mar;12(3):167-72
pubmed: 14694355
Virology. 2000 Jul 5;272(2):267-80
pubmed: 10873770
Am J Physiol Heart Circ Physiol. 2010 Nov;299(5):H1374-81
pubmed: 20833960
Biomedicines. 2022 May 17;10(5):
pubmed: 35625891
Cardiovasc Pathol. 2007 Jul-Aug;16(4):191-202
pubmed: 17637427
Folia Neuropathol. 2019;57(1):41-50
pubmed: 31038187
J Cancer Sci Ther. 2013 Aug 19;5:291-299
pubmed: 25798214
J Thromb Haemost. 2018 Mar;16(3):458-461
pubmed: 29316251
Sci Rep. 2020 Jun 25;10(1):10365
pubmed: 32587281
EMBO Mol Med. 2023 Sep 11;15(9):e17376
pubmed: 37534622
Front Cardiovasc Med. 2022 May 03;9:878199
pubmed: 35592395
Sci Rep. 2020 Feb 11;10(1):2371
pubmed: 32047224
Front Cardiovasc Med. 2021 Feb 16;8:633212
pubmed: 33665212
J Inflamm (Lond). 2019 May 29;16:12
pubmed: 31160886
J Biol Chem. 2006 Mar 24;281(12):8041-50
pubmed: 16407226
J Gen Virol. 2004 May;85(Pt 5):1267-1278
pubmed: 15105544
BMC Plant Biol. 2018 Oct 4;18(1):219
pubmed: 30286719

Auteurs

Kyle Varkoly (K)

Department of Internal Medicine, McLaren Macomb Hospital, Michigan State University College of Human Medicine, 1000 Harrington St., Mt Clemens, MI 48043, USA.

Roxana Beladi (R)

Department of Neurological Surgery, Ascension Providence Hospital, Michigan State University College of Human Medicine, 16001 W Nine Mile Rd., Southfield, MI 48075, USA.

Mostafa Hamada (M)

College of Medicine, Kansas City University, 1750 Independence Ave, Kansas City, MO 64106, USA.
Center for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler St., Tempe, AZ 85287, USA.

Grant McFadden (G)

Center for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler St., Tempe, AZ 85287, USA.

James Irving (J)

UCL Respiratory and the Institute of Structural and Molecular Biology, University College London, 5 University Street, London WC1E 6JF, UK.

Alexandra R Lucas (AR)

Center for Immunotherapy Vaccines and Virotherapy, Biodesign Institute, Arizona State University, 727 E Tyler St., Tempe, AZ 85287, USA.
Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, 727 E Tyler St., Tempe, AZ 85287, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH